Genethon: Clinical Trials

7 trials sponsored by Genethon, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 terminated, 1 active not recruiting. 7 Phase 1, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 17Completed 4, Terminated 2, Active not recruiting 1
Phase 26Completed 3, Terminated 2, Active not recruiting 1

Follow Genethon: new trials by email

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease
Lentiviral G1XCGD Gene Therapy - Granulomatous Disease, Chronic, X-linked
Phase 1 / Phase 2CompletedUniversity of California, Los Angeles102015-10-292025-05-02
Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome
Autologous CD34+ cells transduced with WASP lentiviral vector - Wiskott-Aldrich Syndrome
Phase 1 / Phase 2Active not recruitingGenethon102014-09-012021-06-03
Gene Therapy for X-linked Chronic Granulomatous Disease (X-CGD)
X vivo gene therapy - X-Linked Chronic Granulomatous Disease
Phase 1 / Phase 2TerminatedGenethon32013-06-242026-04-13
Gene Therapy for X-linked Chronic Granulomatous Disease
X vivo gene therapy - X-Linked Chronic Granulomatous Disease
Phase 1 / Phase 2TerminatedGenethon32013-06-242026-04-13
Gene Therapy for WAS
Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene - Wiskott-Aldrich Syndrome
Phase 1 / Phase 2CompletedGenethon52011-05-012018-05-22
Gene Therapy for Wiskott-Aldrich Syndrome (WAS)
Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene - Wiskott-Aldrich Syndrome
Phase 1 / Phase 2CompletedGenethon62011-03-012021-06-03
Clinical Study of AAV1-gamma-sarcoglycan Gene Therapy for Limb Girdle Muscular Dystrophy Type 2C
AAV1-gamma-sarcoglycan vector injection - Limb Girdle Muscular Dystrophy Type 2C, Gamma-sarcoglycanopathy
Phase 1CompletedGenethon92006-11-012011-04-29

Conditions studied

Granulomatous Disease, Chronic (3)  ·  Wiskott-Aldrich Syndrome (3)  ·  Primary Immunodeficiency Diseases (2)  ·  Limb-girdle muscular dystrophy, type 2C (1)  ·  Neuromuscular Diseases (1)  ·  Rare Diseases (1)

Countries

France (4)  ·  United Kingdom (3)  ·  United States (1)

Top investigators

Adrian Thrasher, MD, PHD (1)  ·  Caroline Y. Kuo, MD (1)  ·  Donald B. Kohn, MD (1)  ·  Emma Morris, MD, PHD (1)  ·  Hubert Serve, MD, PHD (1)  ·  Janine Reichenbach, MD (1)  ·  Serge Herson, Prof (1)

Results publications

PMID 35075289, PMID 28716862, PMID 29664709

NIH funding

2009 (1), P01HL073104 (1)